Drug Profile
Research programme: adult stem cell therapeutics - TiGenix
Alternative Names: Cx 602; Cx 603Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cellerix
- Developer TiGenix
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Spain (Intralesional)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in Spain (Intra-articular, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Spain (IV)